Tandem Diabetes Care (TNDM) Q2 2024 earnings summary

Executive summary

• Achieved 13% year-over-year growth in Q2 2024 worldwide sales to $221.9 million, the second-highest in company history, with over 30,000 pumps shipped globally and strong international growth.

• Tandem Mobi launched in the US with Dexcom G7 integration, attracting a younger demographic and new customers, with over half of Mobi users new to the company and a majority converting from multiple daily injections (MDI).

• Expanded prescriber base and positive feedback from healthcare providers and patients, highlighting improved quality of life and satisfaction.

• Completed pivotal study enrollment for Control-IQ expansion to type 2 diabetes and advanced product pipeline, including extended wear infusion set trial.

• Ended Q2 with $452.4 million in cash, cash equivalents, and short-term investments.

Financial highlights

• Q2 2024 worldwide sales: $221.9 million (US: $156.7 million, up 10%; International: $65.2 million, up 22% YoY); gross margin 51% (down from 52% YoY).

• Net loss for Q2 2024 was $30.8 million, improved from $35.8 million in Q2 2023; adjusted EBITDA margin was -1%.

• Six-month sales: $415 million in 2024, up from $365.3 million in 2023.

• Operating expenses: $143.6 million in Q2 2024, with R&D up 15% and SG&A down 3% YoY.

• Convertible notes outstanding: $357 million principal (2025 and 2029 maturities), both at 1.5% interest.

Outlook and guidance

• Raised 2024 sales guidance to $885–$892 million (15% YoY growth); Q3 2024 guidance: $222–$225 million worldwide.

• US sales expected at $640–$645 million; international at $245–$247 million for 2024.

• Maintaining full-year gross margin expectation of 51% and break-even adjusted EBITDA.

• Management expects continued growth in pump shipments and installed base, with renewal sales to increase as more warranties expire.

• Cash position and projected cash flows expected to fund operations for at least the next 12 months.